Zevra Therapeutics (ZVRA) Cash & Current Investments: 2014-2025
Historic Cash & Current Investments for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $199.5 million.
- Zevra Therapeutics' Cash & Current Investments rose 123.22% to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.2 million, marking a year-over-year increase of 106.20%. This contributed to the annual value of $69.5 million for FY2024, which is 2.60% up from last year.
- Zevra Therapeutics' Cash & Current Investments amounted to $199.5 million in Q3 2025, which was down 1.53% from $202.6 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Cash & Current Investments registered a high of $202.6 million during Q2 2025, and its lowest value of $49.3 million during Q2 2024.
- For the 3-year period, Zevra Therapeutics' Cash & Current Investments averaged around $94.3 million, with its median value being $74.6 million (2023).
- Per our database at Business Quant, Zevra Therapeutics' Cash & Current Investments skyrocketed by 3,122.28% in 2021 and then slumped by 43.31% in 2024.
- Quarterly analysis of 5 years shows Zevra Therapeutics' Cash & Current Investments stood at $112.3 million in 2021, then dropped by 26.69% to $82.4 million in 2022, then declined by 17.76% to $67.7 million in 2023, then climbed by 2.60% to $69.5 million in 2024, then soared by 123.22% to $199.5 million in 2025.
- Its last three reported values are $199.5 million in Q3 2025, $202.6 million for Q2 2025, and $62.6 million during Q1 2025.